The Obesity Paradox in Kidney Disease: How to Reconcile It With Obesity Management

Kidney International Reports

Volumn 2, Issue 2, 2017, Pages 271-281

  Kalantar Zadeh, Kamyar ^a,b,c,d   Rhee, Connie M ^a   Chou, Jason ^a   Ahmadi, S Foad ^a,b   Park, Jongha ^d   Chen, Joline L T ^d   Amin, Alpesh N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

biologic plausibility; body mass index; fat mass; muscle mass; obesity paradox; protein energy wasting; reverse epidemiology

Indexed keywords

EID: 85020657487     PISSN: 24680249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ekir.2017.01.009     Document Type: Review

References (92)

1. Saran, R., Li, Y., Robinson, B., et al. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 67:3 suppl 1 (2016), S1–S305.
2. Kalantar-Zadeh K, Kovesdy CP, Streja E, et al. Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced CKD. Nephrol Dial Transplant., in press.
3. Li, L., Kalantar-Zadeh, K., Obesity that makes kidney cancer more likely but helps fight it more strongly. J Natl Cancer Inst 105 (2013), 1848–1849.
4. Besarab, A., Bolton, W.K., Browne, J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998), 584–590.
5. Eknoyan, G., Beck, G.J., Cheung, A.K., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 (2002), 2010–2019.
6. Paniagua, R., Amato, D., Vonesh, E., et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13 (2002), 1307–1320.
7. EVOLVE Trial Investigators, Chertow, G.M., Block, G.A., Correa-Rotter, R., et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 (2012), 2482–2494.
8. Thadhani, R., Appelbaum, E., Pritchett, Y., et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307 (2012), 674–684.
9. Kovesdy, C.P., Lu, J.L., Molnar, M.Z., et al. Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med 174 (2014), 1442–1449.
10. Fellstrom, B.C., Jardine, A.G., Schmieder, R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009), 1395–1407.
11. Park, J., Ahmadi, S.F., Streja, E., et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis 56 (2014), 415–425.
12. Rhee, C.M., Nguyen, D.V., Moradi, H., et al. Association of adiponectin with body composition and mortality in hemodialysis patients. Am J Kidney Dis 66 (2015), 313–321.
13. Park, C., Obi, Y., Streja, E., et al. Serum uric acid, protein intake and mortality in hemodialysis patients. Nephrol Dial Transplant, 2017 [epub] http://dx.doi.org/10.1093/ndt/gfw419.
14. Kalantar-Zadeh, K., Block, G., Humphreys, M.H., Kopple, J.D., Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63 (2003), 793–808.
15. Kalantar-Zadeh, K., Block, G., Horwich, T., Fonarow, G.C., Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43 (2004), 1439–1444.
16. Ahmadi, S.F., Streja, E., Zahmatkesh, G., et al. Reverse epidemiology of traditional cardiovascular risk factors in the geriatric population. J Am Med Dir Assoc 16 (2015), 933–939.
17. Kalantar-Zadeh, K., Rhee, C.M., Amin, A.N., To legitimize the contentious obesity paradox. Mayo Clin Proc 89 (2014), 1033–1035.
18. Doshi, M., Streja, E., Rhee, C.M., et al. Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis. Nephrol Dial Transplant 31 (2016), 1310–1319.
19. Rhee, C.M., Ahmadi, S.F., Kalantar-Zadeh, K., The dual roles of obesity in chronic kidney disease: a review of the current literature. Curr Opin Nephrol Hypertens 25 (2016), 208–216.
20. Lu, J.L., Molnar, M.Z., Naseer, A., et al. Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol 3 (2015), 704–714.
21. Friedman, A.N., Wolfe, B., Is bariatric surgery an effective treatment for type II diabetic kidney disease?. Clin J Am Soc Nephrol 11 (2016), 528–535.
22. Friedman, A.N., Quinney, S.K., Inman, M., et al. Influence of dietary protein on glomerular filtration before and after bariatric surgery: a cohort study. Am J Kidney Dis 63 (2014), 598–603.
23. Kovesdy, C.P., Furth, S.L., Zoccali, C., World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. Kidney Int, 2016, 10.1016/j.kint.2016.10.019.
24. Ahmadi, S.F., Zahmatkesh, G., Ahmadi, E., et al. Association of body mass index with clinical outcomes in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. Cardiorenal Med 6 (2015), 37–49.
25. Ahmadi, S.F., Zahmatkesh, G., Streja, E., et al. Body mass index and mortality in kidney transplant recipients: a systematic review and meta-analysis. Am J Nephrol 40 (2014), 315–324.
26. Park, J., Jin, D.C., Molnar, M.Z., et al. Mortality predictability of body size and muscle mass surrogates in Asian vs white and African American hemodialysis patients. Mayo Clin Proc 88 (2013), 479–486.
27. Kalantar-Zadeh, K., Regidor, D.L., Kovesdy, C.P., et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation 119 (2009), 671–679.
28. Kalantar-Zadeh, K., Ahmadi, S.F., Carrying a heavier weight is healthy: obesity-reinforced fitness hypothesis in metabolically healthy obesity. Obesity (Silver Spring) 24 (2016), 281–282.
29. Dulloo, A.G., Jacquet, J., Girardier, L., Autoregulation of body composition during weight recovery in human: the Minnesota Experiment revisited. Int J Obes Relat Metab Disord 20 (1996), 393–405.
30. Dulloo, A.G., A role for suppressed skeletal muscle thermogenesis in pathways from weight fluctuations to the insulin resistance syndrome. Acta Physiol Scand 184 (2005), 295–307.
31. Oreopoulos, A., Kalantar-Zadeh, K., McAlister, F.A., et al. Comparison of direct body composition assessment methods in patients with chronic heart failure. J Card Fail 16 (2010), 867–872.
32. Bross, R., Chandramohan, G., Kovesdy, C.P., et al. Comparing body composition assessment tests in long-term hemodialysis patients. Am J Kidney Dis 55 (2010), 885–896.
33. Kalantar-Zadeh, K., Dunne, E., Nixon, K., et al. Near infra-red interactance for nutritional assessment of dialysis patients. Nephrol Dial Transplant 14 (1999), 169–175.
34. Noori, N., Kopple, J.D., Kovesdy, C.P., et al. Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 5 (2010), 2258–2268.
35. Kalantar-Zadeh, K., Block, G., Kelly, M.P., et al. Near infra-red interactance for longitudinal assessment of nutrition in dialysis patients. J Ren Nutr 11 (2001), 23–31.
36. Noori, N., Kovesdy, C.P., Bross, R., et al. Novel equations to estimate lean body mass in maintenance hemodialysis patients. Am J Kidney Dis 57 (2011), 130–139.
37. Patel, S.S., Molnar, M.Z., Tayek, J.A., et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle 4 (2013), 19–29.
38. Kalantar-Zadeh, K., Kuwae, N., Wu, D.Y., et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 83 (2006), 202–210.
39. Noori, N., Kovesdy, C.P., Dukkipati, R., et al. Survival predictability of lean and fat mass in men and women undergoing maintenance hemodialysis. Am J Clin Nutr 92 (2010), 1060–1070.
40. Wang, J., Streja, E., Rhee, C.M., et al. Lean body mass and survival in hemodialysis patients and the roles of race and ethnicity. J Ren Nutr 26 (2016), 26–37.
41. Postorino, M., Marino, C., Tripepi, G., Zoccali, C., Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol 53 (2009), 1265–1272.
42. Kalantar-Zadeh, K., Streja, E., Kovesdy, C.P., et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 85 (2010), 991–1001.
43. Kalantar-Zadeh, K., Streja, E., Molnar, M.Z., et al. Mortality prediction by surrogates of body composition: an examination of the obesity paradox in hemodialysis patients using composite ranking score analysis. Am J Epidemiol 175 (2012), 793–803.
44. Beddhu, S., Pappas, L.M., Ramkumar, N., Samore, M., Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 14 (2003), 2366–2372.
45. Ahmadi, S.F., Zahmatkesh, G., Streja, E., et al. Association of body mass index with mortality in peritoneal dialysis patients: a systematic review and meta-analysis. Perit Dial Int 36 (2016), 315–325.
46. Park, J., Mehrotra, R., Rhee, C.M., et al. Serum creatinine level, a surrogate of muscle mass, predicts mortality in peritoneal dialysis patients. Nephrol Dial Transplant 28 (2013), 2146–2155.
47. Streja, E., Park, J., Chan, T.Y., et al. Erythropoietin dose and mortality in hemodialysis patients: marginal structural model to examine causality. Int J Nephrol, 2016, 2016, 6087134.
48. Lertdumrongluk, P., Streja, E., Rhee, C.M., et al. Dose of hemodialysis and survival: a marginal structural model analysis. Am J Nephrol 39 (2014), 383–391.
49. Lukowsky, L.R., Mehrotra, R., Kheifets, L., et al. Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis. Clin J Am Soc Nephrol 8 (2013), 619–628.
50. Miller, J.E., Molnar, M.Z., Kovesdy, C.P., et al. Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf 21 (2012), 1232–1239.
51. Chang, T.I., Ngo, V., Streja, E., et al. Association of body weight changes with mortality in incident hemodialysis patients. Nephrol Dial Transplant, 2016/2017 [epub] http://dx.doi.org/10.1093/ndt/gfw373.
52. Glanton, C.W., Hypolite, I.O., Hshieh, P.B., et al. Factors associated with improved short term survival in obese end stage renal disease patients. Ann Epidemiol 13 (2003), 136–143.
53. Johansen, K.L., Young, B., Kaysen, G.A., Chertow, G.M., Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 80 (2004), 324–332.
54. Ricks, J., Molnar, M.Z., Kovesdy, C.P., et al. Racial and ethnic differences in the association of body mass index and survival in maintenance hemodialysis patients. Am J Kidney Dis 58 (2011), 574–582.
55. Grabowski, D.C., Ellis, J.E., High body mass index does not predict mortality in older people: analysis of the Longitudinal Study of Aging. J Am Geriatr Soc 49 (2001), 968–979.
56. Horwich, T.B., Fonarow, G.C., Hamilton, M.A., et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38 (2001), 789–795.
57. Kalantar-Zadeh, K., Horwich, T.B., Oreopoulos, A., et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 10 (2007), 433–442.
58. Kalantar-Zadeh, K., Rhee, C., Sim, J.J., et al. Why cachexia kills: examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle 4 (2013), 89–94.
59. Rothman, K.J., Greenland, S., Causation and causal inference in epidemiology. Am J Public Health 95:suppl 1 (2005), S144–S150.
60. Hill, A.B., The environment and disease: association or causation?. Proc R Soc Med 58 (1965), 295–300.
61. Whittemore, A., Altshuller, B., Lung cancer incidence in cigarette smokers: further analysis of Doll and Hill's data for British physicians. Biometrics 32 (1976), 805–816.
62. Howick, J., Glasziou, P., Aronson, J.K., The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute?. J R Soc Med 102 (2009), 186–194.
63. Mehrotra, R., Kopple, J.D., Nutritional management of maintenance dialysis patients: why aren't we doing better?. Annu Rev Nutr 21 (2001), 343–379.
64. Kalantar-Zadeh, K., Ikizler, T.A., Block, G., et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 42 (2003), 864–881.
65. Balakrishnan, V.S., Guo, D., Rao, M., et al. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int 65 (2004), 1449–1460.
66. Stenvinkel, P., Inflammation in end-stage renal disease—a fire that burns within. Contrib Nephrol 149 (2005), 185–199.
67. Yao, Q., Lindholm, B., Stenvinkel, P., Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int 8 (2004), 118–129.
68. Kalantar-Zadeh, K., Block, G., McAllister, C.J., et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 80 (2004), 299–307.
69. Zimmermann, J., Herrlinger, S., Pruy, A., et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55 (1999), 648–658.
70. Qureshi, A.R., Alvestrand, A., Divino-Filho, J.C., et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13:suppl 1 (2002), S28–S36.
71. Kalantar-Zadeh, K., Kopple, J.D., Humphreys, M.H., Block, G., Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 19 (2004), 1507–1519.
72. Ling, P.R., Smith, R.J., Kie, S., et al. Effects of protein malnutrition on IL-6-mediated signaling in the liver and the systemic acute-phase response in rats. Am J Physiol Regul Integr Comp Physiol 287 (2004), R801–R808.
73. Kovesdy, C.P., Anderson, J.E., Kalantar-Zadeh, K., Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 18 (2007), 304–311.
74. Kalantar-Zadeh, K., Kopple, J.D., Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 38 (2001), 1343–1350.
75. Lowrie, E.G., Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients. Am J Kidney Dis 32:6 suppl 4 (1998), S105–S112.
76. Collins, S., Myatt, M., Short-term prognosis in severe adult and adolescent malnutrition during famine: use of a simple prognostic model based on counting clinical signs. JAMA 284 (2000), 621–626.
77. de Mutsert, R., Snijder, M.B., van der Sman-de Beer, F., et al. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 18 (2007), 967–974.
78. Foley, R.N., Parfrey, P.S., Sarnak, M.J., Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:12 suppl (1998), S16–S23.
79. Collins, A.J., Foley, R.N., Herzog, C., et al. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis, 57(1 suppl 1), 2011 A8, e1–526.
80. Snyder, J.J., Foley, R.N., Gilbertson, D.T., et al. Body size and outcomes on peritoneal dialysis in the United States. Kidney Int 64 (2003), 1838–1844.
81. McDonald, S.P., Collins, J.F., Johnson, D.W., Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol 14 (2003), 2894–2901.
82. Weber, M.A., Neutel, J.M., Smith, D.H., Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. J Am Coll Cardiol 37 (2001), 169–174.
83. Schrier, R.W., Abraham, W.T., Hormones and hemodynamics in heart failure. N Engl J Med 341 (1999), 577–585.
84. McIntyre, C.W., Burton, J.O., Selby, N.M., et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 3 (2008), 19–26.
85. McIntyre, C.W., Recurrent circulatory stress: the dark side of dialysis. Semin Dial 23 (2010), 449–451.
86. Park, J., Rhee, C.M., Sim, J.J., et al. A comparative effectiveness research study of the change in blood pressure during hemodialysis treatment and survival. Kidney Int 84 (2013), 795–802.
87. Feldman, A.M., Combes, A., Wagner, D., et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35 (2000), 537–544.
88. Mohamed-Ali, V., Goodrick, S., Bulmer, K., et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 277 (1999), E971–E975.
89. Jandacek, R.J., Anderson, N., Liu, M., et al. Effects of yo-yo diet, caloric restriction, and olestra on tissue distribution of hexachlorobenzene. Am J Physiol Gastrointest Liver Physiol 288 (2005), G292–G299.
90. Rauchhaus, M., Coats, A.J., Anker, S.D., The endotoxin-lipoprotein hypothesis. Lancet 356 (2000), 930–933.
91. Niebauer, J., Volk, H.D., Kemp, M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353 (1999), 1838–1842.
92. Molnar, M.Z., Streja, E., Kovesdy, C.P., et al. High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients. Am J Clin Nutr 94 (2011), 945–954.